Included studies | Comparisons | Pairwise meta-analysis | ||
---|---|---|---|---|
WMD(95%CI) | I2 | Ph | ||
The total blood loss (PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:12697586;PMID:11476309;PMID:10673876; PMID:8636182) | ||||
1 study | IV vs. control | −277.34 (−431.85–122.83) | NA | NA |
1 study | Topical vs. control | −307.78 (−460.92–154.64) | NA | NA |
1 study | Topical vs. IV | −30.44 (−163.81–102.93) | NA | NA |
2 studies | IV + topical vs. IV | −218.13 (−282.59–153.68) | 46.8% | 0.17 |
1 study | Oral vs. topical | −83.60 (−203.84–36.64) | NA | NA |
1 study | T VS. IV + topical | 956.60 (829.31–1083.89) | NA | NA |
6 studies | IV + T vs. T | −156.09 (−179.41–132.78) | 98.1% | <0.01 |
2 studies | Topical+T vs. T | −79.20 (−106.34–52.05) | 87.6% | <0.01 |
3 studies | Topical+T vs. IV + T | 10.90 (−7.95–29.72) | 62.5% | 0.07 |
1 study | IV + topical+T vs. IV + topical | 106.80 (13.04–200.56) | NA | NA |
1 study | IV + topical+T vs. T | −849.80(−987.51–712.09) | NA | NA |
Transfusion risk (PMID:29544472;PMID:29257010;PMID:27267228;PMID:26507526;PMID:27222617;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:11476309;PMID:10673876) | ||||
1 study | IV vs. control | 0.23 (0.08–0.74) | NA | NA |
1 study | Topical vs. control | 0.35 (0.13–1.00) | NA | NA |
1 study | Topical vs. IV | 1.48 (0.43–5.14) | NA | NA |
1 study | IV + topical vs. IV | 0.24 (0.03–2.23) | NA | NA |
1 study | Oral vs. topical | 0.73 (0.16–3.38) | NA | NA |
1 study | T VS. IV + topical | 20.20 (1.13–360.28) | NA | NA |
5 studies | IV + T vs. T | 0.09 (0.04–0.17) | 0% | 0.77 |
3 studies | Topical+T vs. T | 0.19 (0.10–0.37) | 46.2% | 0.16 |
3 studies | Topical+T vs. IV + T | 0.99 (0.34–2.85) | 0% | 0.76 |
1 study | IV + Topical+T vs. T | 0.05 (0.00–0.88) | NA | NA |
The change of Hb (PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:24768543;PMID:11476309) | ||||
1 study | IV vs. control | 1.17 (0.54–1.80) | NA | NA |
1 study | Topical vs. control | 1.42 (0.78–2.06) | NA | NA |
1 study | Topical vs. IV | 0.25 (−0.32–0.82) | NA | NA |
2 studies | IV + topical vs. IV | 0.67 (0.48–0.86) | 0% | 0.81 |
1 study | Oral vs. topical | 0.20 (−0.13–0.53) | NA | NA |
1 study | T VS. IV + topical | −1.61 (−1.90–1.32) | NA | NA |
3 studies | IV + T vs. T | 2.50 (2.09–2.90) | 94.8% | <0.01 |
2 studies | Topical+T vs. T | 1.42 (0.84–2.00) | 5.4% | 0.30 |
4 studies | Topical+T vs. IV + T | 0.57 (0.31–0.84) | 92.0% | <0.01 |
1 study | IV + topical+T vs. IV + topical | −0.20 (−0.38–0.02) | NA | NA |
1 study | IV + topical+T vs. T | 1.41 (1.11–1.71) | NA | NA |
DVT (PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:10673876; PMID:8636182) | ||||
1 study | IV + topical vs. IV | 0.33 (0.01–8.35) | NA | NA |
3 studies | IV + T vs.T | 0.80 (0.24–2.63) | 0% | 0.50 |
1 study | Topical+T vs. IV + T | 0.55 (0.05–6.21) | NA | NA |
PE (PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:10673876;PMID:8636182) | ||||
1 study | IV + topical vs. IV | 0.33 (0.01–8.35) | NA | NA |
2 studies | IV + T vs. T | 0.22 (0.24–2.14) | 0% | 0.83 |
1 study | Topical+T vs. IV + T | 0.55 (0.05–6.21) | NA | NA |